Drug Promotion - What We Know, What We Have Yet to Learn - Reviews of Materials in the WHO/HAI Database on Drug Promotion - EDM Research Series No. 032
(2004; 102 pages) View the PDF document
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contentsIntroduction
Open this folder and view contentsReview 1. What attitudes do professional and lay people have to promotion?
Open this folder and view contentsReview 2. What impact does pharmaceutical promotion have on attitudes and knowledge?
Close this folderReview 3. What impact does pharmaceutical promotion have on behaviour?
View the document3.1 Impact of promotion on individual prescribing practices
View the document3.2 Self-reported reasons for prescribing changes
View the document3.3 Prescribing by those who rely on commercial information
View the document3.4 Prescribing and exposure to promotion
View the document3.5 Exploring the impact of samples on prescribing
View the documentSummary
View the document3.6 Impact of promotion on overall sales
View the document3.7 Impact of promotion and industry funding on requests for formulary additions
View the document3.8 DTCA and consumers’ decisions
View the document3.9 Impact of sponsorship on content of continuing medical education courses
View the document3.10 Impact of industry funding on research
View the document3.11 Does funding affect the research agenda?
View the document3.12 Do authors reveal funding sources?
View the documentSummary of conclusions
Open this folder and view contentsReview 4. What interventions have been tried to counter promotional activities, and with what results?
View the documentFinal conclusions
View the documentReferences
 

Summary

Doctors’ own assessments of whether promotion affects their prescribing are of limited value in establishing whether this is the case. The research clearly shows that doctors who report relying more on commercial information, prescribe more heavily, less rationally, and adopt new medicines more quickly. Some researchers have interpreted this finding as showing that ‘relying on pharmaceutical company information increases prescribing’. This interpretation is not justified by evidence from these studies. The studies cannot show whether doctors would prescribe differently if their level of reliance on promotion were to change. Some doctors may have characteristics (such as attitudes, skills) that lead to both reliance on promotion, and heavy or irrational prescribing.

The studies that look at different levels of exposure to promotion (between prescribers or over time) and prescribing provide more convincing evidence that promotion changes behaviour. Further research using this kind of approach would be valuable. Simply replicating the Peay and Peay study in another place, using another drug, would strengthen the evidence considerably: similar findings would add substantial weight to the argument that contact with sales representatives does change prescribing behaviour. In addition, other studies that look at prescribing changes after exposure to promotion would be very useful. Cormack and Howells105 and Strickland-Hodge and Jepson108 used prescribing data from the Prescription Pricing Authority in the UK. Such data could be utilised further to observe prescribing changes, for example, before and after visits by sales representatives. Other countries where all or most prescriptions are subsidised by the government, such as Australia and New Zealand, have similar data available.

Samples appear to influence prescribing, but this has received little attention and needs further study. Other literature122,124,125 has highlighted the widespread misuse of samples by health professionals, sales representatives and others, but ironically less is known about their use for patients.

Marketing literature tends to assume that evidence of behaviour changes is a good outcome: it shows investment in advertising is worthwhile. The public health and medical based literature tends to assume that higher prescribing levels of what is judged to be a sub-optimal medicine will lead to worse health outcomes. Some of the research suggesting that doctors who rely heavily on promotion prescribe differently does explicitly look at the quality of the prescribing (e.g., Haayer’s104 use of an expert panel, or the extent of chloramphenicol prescribing in the study by Becker et al.102). Such measures of appropriateness need to be used more.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014